Chapter 7 of 25
What you will learn
- Understand the different questions answered by ultrasound, MRI, CT and PET-CT.
- Recognize the limits of scan-based staging.
- Prepare safely and ask why a test is needed.
Local assessment
Expert transvaginal ultrasound and pelvic MRI can assess the uterine tumour, depth of myometrial invasion and possible cervical involvement. MRI provides detailed soft-tissue images and is particularly useful when fertility preservation or local extent needs careful assessment. The quality of interpretation matters; a specialist review can be more informative than simply repeating a test.
Neither test can exclude every microscopic focus. After hysterectomy, the pathologist measures invasion directly and examines tissue not visible on imaging. An imaging impression of “confined to the uterus” is therefore a working assessment, not a guarantee that the final stage will remain unchanged.
Looking beyond the uterus
CT of the chest, abdomen and pelvis may be used for aggressive histology, suspected extrauterine disease, concerning symptoms or planning advanced-disease treatment. It can assess lungs, liver, peritoneum and enlarged lymph nodes. A small lymph node can contain cancer and a large node can be reactive, so size alone does not settle every question.
PET-CT combines metabolic imaging with CT and is useful in selected situations, such as clarifying suspected recurrence or uncertain metastatic findings when the result would change management. Inflammation can also take up tracer. PET-CT is not automatically required for every newly diagnosed low-risk cancer and is not a replacement for tissue confirmation when an uncertain finding is decisive.
Choosing the right test
| Clinical question | Possible approach |
|---|---|
| Is there a focal lining lesion? | Ultrasound and hysteroscopy with sampling |
| Is muscle or cervical invasion suspected? | Pelvic MRI or expert ultrasound |
| Is there disease outside the pelvis? | CT, with selected additional testing |
| Would an uncertain recurrence alter a major treatment decision? | Targeted imaging and sometimes biopsy |
| Is an asymptomatic low-risk survivor well? | Clinical follow-up; routine PET-CT is usually not justified |
Blood tests assess anaemia, kidney or liver function and treatment fitness rather than proving the absence of cancer. CA-125 may be useful in selected patients, particularly if previously elevated or in some advanced presentations, but it is neither a screening test nor a universal measure of tumour activity.
Safety and practical preparation
Tell the imaging team about pregnancy possibility, kidney disease, previous contrast reactions and implanted devices. MRI does not use ionizing radiation, but some implants require specific checks. CT and PET-CT do use radiation; a justified study can provide important benefit, while unnecessary repetition adds burden without necessarily improving care.
Contrast use depends on the clinical question and safety assessment. Instructions about fasting or diabetes medicines vary by scan and centre; follow the written local instructions. If claustrophobia, pain or mobility issues may make a scan difficult, discuss adaptations in advance. Ask how the report will reach the treating team.
Interpreting uncertain findings
Words such as “indeterminate,” “suspicious” and “likely benign” communicate different levels of uncertainty. An incidental lung nodule does not automatically mean stage IV cancer. Comparison with older scans, follow-up imaging or biopsy may be appropriate. Before a major change in treatment intent, ask whether the finding is sufficiently established and whether confirmation is feasible.
Questions and take-home messages
Ask what decision the scan will inform, whether previous images can be reviewed and what happens if the result is inconclusive. Keep access to images as well as written reports when moving between centres. The goal is a coherent staging assessment, not the largest possible collection of tests.
Related chapters
- Understanding the Pathology Report
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- NCI: Endometrial Cancer Treatment PDQ
- ESGO/ESHRE/ESGE fertility-sparing guideline, 2023
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy